Form 4: Rapport Therapeutics Director Robert J. Perez Granted Stock Options

Rapport Therapeutics, Inc. Director Robert J. Perez was granted 10,925 stock options with an exercise price of $10.95, vesting over the next year, as disclosed in a recent SEC Form 4 filing.

Summary

• Robert J. Perez, a Director of Rapport Therapeutics, Inc. (RAPP), was granted 10,925 stock options.
• The options have an exercise price of $10.95 per share.
• The grant date for these options was June 17, 2025.
• The options are set to expire on June 17, 2035.
• Vesting of the shares underlying the option will occur on the earlier of June 17, 2026, or the date of the next Annual Meeting of Stockholders, contingent on Mr. Perez's continued service.

Sentiment

Score: 6

Explanation: The grant of stock options to a director is a standard compensation practice that aligns the director's interests with shareholders, which is generally positive for corporate governance and long-term value creation. It does not indicate any immediate negative or highly positive operational news.

Positives

• The grant of stock options to Director Robert J. Perez aligns his financial interests with those of the company's shareholders, incentivizing long-term performance.
• Equity compensation is a standard practice for attracting and retaining qualified board members.

Negatives

• No specific negatives are identified in this Form 4 filing.

Risks

• The value of the stock options is subject to the future performance of Rapport Therapeutics' stock price, meaning the options could become worthless if the stock price falls below the exercise price.
• The vesting of options is contingent on continued service, posing a risk to the director if service is terminated before vesting.

Future Outlook

The vesting schedule for the stock options, set for the earlier of June 17, 2026, or the next Annual Meeting of Stockholders, indicates an expectation of continued service from Director Robert J. Perez and aligns his future incentives with the company's performance.

Industry Context

The granting of stock options to directors is a common and widely accepted practice across various industries, particularly in publicly traded companies. It serves as a key component of executive and director compensation packages, aiming to align the interests of the board members with those of the shareholders by providing a direct stake in the company's long-term success and stock performance.

Comparison to Industry Standards

• Granting stock options to directors is a standard practice in corporate governance, comparable to compensation structures seen in many biotech and pharmaceutical companies of similar size to Rapport Therapeutics.
• While specific grant sizes vary based on company stage, market capitalization, and individual roles, the mechanism of equity-based compensation like stock options is a global benchmark for incentivizing long-term commitment and performance from board members. No specific comparable companies or projects are mentioned in the filing itself.

Corporate Governance

Related Party Transactions

• The grant of stock options to Robert J. Perez, a Director of Rapport Therapeutics, Inc., constitutes a related party transaction as it involves compensation provided by the company to an insider.

Stakeholder Impact

• Shareholders: The grant of options aims to align the director's interests with shareholders, potentially leading to better long-term decision-making focused on increasing shareholder value.

Next Steps

• The stock options will vest upon the earlier of June 17, 2026, or the date of the next Annual Meeting of Stockholders, subject to continued service.
• Following vesting, the director may choose to exercise the options at the specified exercise price of $10.95 per share.

Key Dates

Keywords

Rapport Therapeutics, RAPP, SEC Form 4, stock options, director compensation, insider transaction, equity grant, beneficial ownership, corporate governance